In Vitro Activity Studies of Doripenem and Two Other Carbapenems Tested Against Pseudomonas aeruginosa and Other Non-Fermentative Bacilli

REFERENCES

• Suárez CJ, Lolans K, Villegas MV, Quinn JP. Mechanisms of resist-ance to beta-lactams in some common Gram-negative bacteria causing noso-comial infections. Expert Rev Anti Infect Ther 2005; 3: 915–922.
   PubMedGoogle Scholar
• Slama TG. Gram-negative antibiotic resistance: there is a price to pay. Crit Care 2008; 12: S4.
   PubMed Web of Science ®Google Scholar
• Bonfiglio G, Russo G, Nicoletti G. Recent development in carbapen-ems. Expert Opin Investig Drugs 2002; 11: 529–544.
   PubMed Web of Science ®Google Scholar
• Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-ab-dominal infections: a focus on the carbapenems. Surg Infect (Larchmt). 2005; 6: 329–343.
   PubMedGoogle Scholar
• Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008; 9: 23–37.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027–1052.
   PubMed Web of Science ®Google Scholar
• EI Gamal MI, Oh CH. Current Status of Carbapenem Antibiotics. Curr Top Med Chem 2010; 8: 1882–1897.
   Google Scholar
• Shakil S, Danishuddin M, Khan AU. Doripenem versus bacteria: an emerging battleground. J Chemother 2009; 21: 482–492.
   PubMed Web of Science ®Google Scholar
• Köhler T, Pechere C. In vitro selection of antibiotic resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 2001; 7: 7–10.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321–331.
   PubMed Web of Science ®Google Scholar
• Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046–5054
   PubMed Web of Science ®Google Scholar
• Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25: 1353–1364.
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007; 45: 3352-3359.
   Google Scholar
• Lambiase A, Catania MR, Del Pezzo M, Rossano F, Terlizzi V, Sepe A, etal. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2011.
   Google Scholar
• McGowan JE Jr. Resistance in nonfermenting Gram-negative bacte-ria: multidrug resistance to the maximum. Am J Med 2006; 119: S29-36; discussion S62-70.
   Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086–3092. Erratum in: Antimicrob Agents Chemother 2010; 54: 3078.
   PubMed Web of Science ®Google Scholar
• Xavier DE, Picao RC, Girardello R, Fehlberg LC, Gales AC. Efflux pumps expression and its association with porin down-regulation and beta-lactamase production among Pseudomonas aeruginosa causing blood-stream infections in Brazil. BMC Microbiol 2010; 12; 10:217.
   Google Scholar
• El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B. Car-bapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns ob-served in clinical isolates. APMIS 2005; 113: 187–196.
   PubMed Web of Science ®Google Scholar
• Peleg AJ, Seifert H, Paterson DL. Acinetobacter baumannii: emer-gence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538–582.
   PubMed Web of Science ®Google Scholar
• Poirel L, Nordmann P. Acquired carbapenem-hydrolyzing filactamases and their genetic support. Curr Pharm Biotechnol 2002; 3: 117–127.
   PubMedGoogle Scholar
• Marque S, Poirel L, Heritier C, Brisse S, Blasco MD, Filip R, et al. Re-gional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J Clin Microbiol 2005; 43: 4885–4888.
   Google Scholar
• Fritsche TR, Sader HS, Toleman MA, Walsh TR, Jones RN. Emerg-ing metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. Clin Infect Dis 2005; 41: S276–278.
   PubMed Web of Science ®Google Scholar
• Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR. Emerging epidemic of metallo-beta-lactamase-mediated resist-ances. Diagn Microbiol Infect Dis 2005; 51: 77–84.
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol In-fect 2005; 11: 974–984.
   PubMed Web of Science ®Google Scholar
• Jones RN, Bell JM, Sader HS, Turnidge JD, Stilwell MG. In vitro po-tency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagn Microbiol Infect Dis 2009; 63: 434–439.
   PubMed Web of Science ®Google Scholar
• Doribax: Doripenem for injection, www.doribax.com (Accessed 17 July 2008).
   Google Scholar
• European Medical Agency, www.emea.europa.eu (Accessed 17 July 2008).
   Google Scholar
• Davies TA, Shang W, Bush K, Flamm RK. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 1510–1512.
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with vari-ous betalactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52: 71–74.
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother 2004; 48: 1313–1319.
   PubMed Web of Science ®Google Scholar
• Rahal JJ. Antimicrobial resistance among and therapeutic options against gramnegative pathogens. Clin Infect Dis 2009; 49: S4–10.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL Acinetobacter baumannii: emer-gence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538–582.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other non-fermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009; 63: 426–433.
   PubMed Web of Science ®Google Scholar
• Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob. Agents Chemother 2008; 52: 4388–4399.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Anan N, Sugimori G, Watanabe T, Jinushi Y, Yoshida I, et al. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int J Antimicrob Agents 2009; 34: 523–528.
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against con-temporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004; 54: 144–154.
   PubMed Web of Science ®Google Scholar
• Christiansen KJ, lp M, Ker HB, Mendoza M, Hsu L, Kiratisin P et al. In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pa-cific region: results of the COMPACT Asia-Pacific Study. Int J Antimicrob Agents 2010; 36: 501–506.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fer-nandez HT. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob Agents Chemother 2008; 52: 761–766.
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (5-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136-3140.
   Google Scholar
• Brown SD, Traczewski MM. Comparative in vitro antimicrobial activ-ity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J Antimicrob Chemother 2005; 55: 944–949.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. BSAC Work-ing Parties on Resistance Surveillance. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bac-teria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62: 55–63.
   Google Scholar
• Jean SS, Hsueh PR, Lee WS, Chang HT, Chou MY, Chen IS, et al. In vitro activities of doripenem and other carbapenems against clinically im-portant bacteria isolated in intensive care units: nationwide data from the SMART Programme. Eur J Clin Microbiol Infect Dis 2010; 29: 471–475.
   PubMed Web of Science ®Google Scholar
• Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia_isolates from both cys-tic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006; 50: 819–821.
   PubMed Web of Science ®Google Scholar
• Chen Y, Garber E, Zhao Q, Ge Y, Wikler MA, Kaniga K, etal. In vitro activity of doripenem (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 2510-2511.
   Google Scholar
• Marti S, Sánchez-Cespedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int J Antimi-crob Agents 2009; 33: 181–182.
   PubMed Web of Science ®Google Scholar
• Esterly JS, Qi C, Malczynski M, Scheetz MH. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status. Pharmacotherapy 2010; 30: 354–360.
   PubMed Web of Science ®Google Scholar
• Ge Y, Wilder MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48: 1384–1396.
   PubMed Web of Science ®Google Scholar
• Lascols C, Legrand P, Merens A, Leclercq R, Armand-Lefevre L, Dru-geon HB, et al. In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter break-points. Eur J Clin Microbiol Infect Dis 2011; 30: 475–482.
   PubMed Web of Science ®Google Scholar
• Betriu C, Gemez M, Lopez-Fabal F, Culebras E, Rodriguez-Avial I, et al. Activity of doripenem against extended-spectrum beta-lactamase-pro-ducing Enterobacteriaceae and Pseudomonas aeruginosa isolates. Eur J Clin Microbiol Infect Dis 2010; 29: 1179–1181.
   PubMed Web of Science ®Google Scholar
• Gomi K, Fujimura S, Fuse K, Takane H, Nakano Y, Kariya Y, et al. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007. J Infect Chemother 2011; 17: 200–206.
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Mantengoli E. Treatment and control of severe infec-tions caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol In-fect 2005; 11: 17–32.
   PubMed Web of Science ®Google Scholar
• Naesens R, Jansens H, Goossens H, leven M, Vlieghe E. Potential of doripenem for the treatment of infections with multidrug-resistant Pseudomonas spp. Int J Antimicrob Agents 2010; 35: 514–515.
   Google Scholar
• Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43: S100–105.
   PubMed Web of Science ®Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acine-tobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43: S49–56.
   Web of Science ®Google Scholar
• Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of car-bapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 2006; 59: 220–228.
   PubMed Web of Science ®Google Scholar
• Tanimoto K, Tomita H, Fujimoto S, Okuzumi K, Ike Y. Fluoro-quinolone enhances the mutation frequency for meropenem-selected car-bapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob Agents Chemother 2008; 52: 3795–3800.
   PubMed Web of Science ®Google Scholar
• Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cys-tic fibrosis. Clin Microbiol Rev 2002; 15: 194–222.
   PubMed Web of Science ®Google Scholar
• Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008; 7: 123–127. MT. FERA - S. ZUMMO - A. DE SARRO
   PubMed Web of Science ®Google Scholar
• Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmunol 2002; 34: 91–100.
   PubMed Web of Science ®Google Scholar
• Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-p-lacta-mases: the quiet before the storm? Clin. Microbiol. Rev 2005; 18: 306–325.
   Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases Clin Microbiol Rev 2007; 20: 440–458.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Threat from the pink corner. Ann Med 2003; 35: 226–234.
   PubMed Web of Science ®Google Scholar
• Walsh TR. Clinically significant carbapenemases: an update. Curr Opin Infect Dis 2008; 21: 367–371.
   PubMed Web of Science ®Google Scholar
• Credito K, Kosowska-Shick K, Appelbaum PC. Mutant prevention concentrations of four carbapenems against Gram-negative rods. Antimi-crob Agents Chemother 2010; 54: 2692–2695.
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Strabala PA, Jones RN. P2087 Spectrum and activity of doripenem, an investigational carbapenem, tested against bac-terial pathogens recovered from patients hospitalised with pneumonia (Eu-rope; 2004-2006). Int J Antimicrob Agents 2007; 29: S2.
   PubMedGoogle Scholar